Kura Oncology, Inc.

KURA

$10.76

Name : Kura Oncology, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $957,216,256.00

EPSttm : -3.32

Kura Oncology, Inc.

$10.76

0.92%

$0.1

KURA — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

17.15

Margin Of Safety %

Put/Call OI Ratio

0.72

EPS Next Q Diff

-0.01

EPS Last/This Y

0.02

EPS This/Next Y

0.87

Price

10.76

Target Price

Analyst Recom

1.2

Performance Q

-1.28

Upside

-1,192.9%

Beta

0.46

Ticker: KURA

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-08-28	KURA	12.64	0.42	1.39	13542
2026-08-31	KURA	12.64	0.45	0.62	14018
2026-09-02	KURA	13.12	0.45	0.41	14772
2026-09-03	KURA	13.15	0.45	1.06	15128
2026-09-04	KURA	13.26	0.44	1.07	15851
2026-09-08	KURA	12.52	0.44	1.64	16225
2026-09-09	KURA	12.09	0.44	1.12	16372
2026-09-10	KURA	11.57	0.45	5.50	17240
2026-09-11	KURA	11.38	0.51	0.75	18335
2026-09-14	KURA	11.56	0.44	0.98	21039
2026-09-15	KURA	11.31	0.44	1.52	21653
2026-09-16	KURA	11.2	0.46	1.11	22088
2026-09-17	KURA	11.7	0.47	0.66	22660
2026-09-18	KURA	11.73	0.48	1.33	23159
2026-09-21	KURA	11.6	0.78	1.39	15007
2026-09-22	KURA	11.75	0.77	1.17	16314
2026-09-23	KURA	11.04	0.80	1.77	17013
2026-09-24	KURA	10.86	0.82	1.16	17753
2026-09-25	KURA	10.76	0.72	0.91	19352
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-08-28	KURA	12.66	6.4	-8.0	-3.19
2026-08-31	KURA	12.63	6.4	-29.2	-3.19
2026-09-01	KURA	12.89	6.4	-40.9	-3.19
2026-09-02	KURA	13.11	6.4	13.5	-3.19
2026-09-03	KURA	13.12	6.4	21.4	-3.19
2026-09-04	KURA	13.26	6.4	17.8	-3.19
2026-09-08	KURA	12.51	5.1	48.2	-3.16
2026-09-09	KURA	12.08	5.1	39.2	-3.16
2026-09-10	KURA	11.58	5.1	42.9	-3.16
2026-09-11	KURA	11.37	5.1	31.3	-3.16
2026-09-14	KURA	11.56	5.1	13.1	-3.16
2026-09-15	KURA	11.31	5.1	33.2	-3.16
2026-09-16	KURA	11.31	5.1	33.2	-3.16
2026-09-17	KURA	11.70	5.1	-2.3	-3.16
2026-09-18	KURA	11.73	5.1	21.7	-3.16
2026-09-21	KURA	11.60	5.1	27.4	-3.16
2026-09-22	KURA	11.73	5.1	15.7	-3.16
2026-09-23	KURA	11.03	5.1	53.5	-3.16
2026-09-24	KURA	10.86	5.1	29.9	-3.16
2026-09-25	KURA	10.76	5.1	26.8	-3.16
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-08-28	KURA	2.59	3.10	15.19
2026-08-31	KURA	2.59	3.12	15.19
2026-09-01	KURA	2.58	3.12	15.19
2026-09-02	KURA	2.58	3.12	15.19
2026-09-03	KURA	2.58	3.12	15.19
2026-09-04	KURA	2.58	3.12	15.19
2026-09-08	KURA	2.58	3.07	15.19
2026-09-09	KURA	2.58	3.07	15.19
2026-09-10	KURA	2.58	3.07	15.19
2026-09-11	KURA	2.58	3.07	15.53
2026-09-14	KURA	2.59	3.09	15.53
2026-09-15	KURA	2.59	3.09	15.53
2026-09-16	KURA	2.59	3.09	15.53
2026-09-17	KURA	2.59	3.09	15.53
2026-09-18	KURA	2.59	3.09	15.53
2026-09-21	KURA	2.59	3.08	15.53
2026-09-23	KURA	2.59	3.08	15.53
2026-09-24	KURA	2.59	3.08	15.53
2026-09-25	KURA	2.59	3.08	17.15
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.77

Avg. EPS Est. Current Quarter

-0.81

Avg. EPS Est. Next Quarter

-0.78

Insider Transactions

2.59

Institutional Transactions

3.08

Beta

0.46

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

55.5

Max Drawdown 5-Year %

-76.5

Target Price

P/E

Forward P/E

PEG

P/S

12.4

P/B

19.76

P/Free Cash Flow

EPS

-3.36

Average EPS Est. Cur. Y

-3.16

EPS Next Y. (Est.)

-2.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-384.3

Relative Volume

0.62

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

EPS 1 30Days Diff

0.28

EBIT Estimation

26.8

◆ KURA Healthcare

$10.76

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

4/20

Pullback

21/25

Volume

9/15

Valuation

10/20

TP/AR

2/10

Options

4/10

RSI

39.3

Range 1M

6.8%

Sup Dist

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

2/25

Growth

15/30

Estimates

0/20

Inst/Vol

5/15

Options

3/10

EPS Yr

-1.3%

EPS NY

26.3%

52W%

53.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +197.4% upside

Quality

6/30

Valuation

15/30

Growth

10/25

Stability

8/10

LT Trend

0/5

Upside

+197.4%

Quality

KURA — P/E HistoricalBiotechnology

Kura Oncology, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 260

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

KURA

Latest News

—

Caricamento notizie per KURA…

stock quote shares KURA – Kura Oncology, Inc. Stock Price stock today

news today KURA – Kura Oncology, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KURA – Kura Oncology, Inc. yahoo finance google finance

stock history KURA – Kura Oncology, Inc. invest stock market

stock prices KURA premarket after hours

ticker KURA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: KURA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y